PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · Real-Time Price · USD
1.100
-0.010 (-0.90%)
Mar 31, 2025, 1:17 PM EDT - Market open

PMV Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Selling, General & Admin
26.9224.2525.0521.811.01
Upgrade
Research & Development
57.9355.8951.9936.4923.93
Upgrade
Operating Expenses
84.8580.1377.0458.2934.94
Upgrade
Operating Income
-84.85-80.13-77.04-58.29-34.94
Upgrade
Interest & Investment Income
10.6611.173.630.450.65
Upgrade
Other Non Operating Income (Expenses)
-0.0200.090.02-0.14
Upgrade
EBT Excluding Unusual Items
-74.21-68.96-73.33-57.82-34.43
Upgrade
Merger & Restructuring Charges
-0.6----
Upgrade
Pretax Income
-74.81-68.96-73.33-57.82-34.43
Upgrade
Income Tax Expense
-16.10-0.010.020.01
Upgrade
Net Income
-58.71-68.96-73.32-57.85-34.44
Upgrade
Net Income to Common
-58.71-68.96-73.32-57.85-34.44
Upgrade
Shares Outstanding (Basic)
5248464514
Upgrade
Shares Outstanding (Diluted)
5248464514
Upgrade
Shares Change (YoY)
7.42%5.31%1.01%214.23%373.26%
Upgrade
EPS (Basic)
-1.14-1.44-1.61-1.28-2.40
Upgrade
EPS (Diluted)
-1.14-1.44-1.61-1.28-2.40
Upgrade
Free Cash Flow
-51.94-56.62-71.74-47.92-32.89
Upgrade
Free Cash Flow Per Share
-1.01-1.18-1.57-1.06-2.29
Upgrade
EBITDA
-83.71-78.88-76.73-57.99-34.62
Upgrade
D&A For EBITDA
1.141.260.320.310.32
Upgrade
EBIT
-84.85-80.13-77.04-58.29-34.94
Upgrade
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q